NASDAQ:OCUP

Delisted

Ocuphire Pharma Stock News

Healthcare > Biotechnology

Buy OCUP

*Your capital is at risk

$1.17

+0 (+0%)

At Close: Jan 22, 2025

Here's Why Momentum in Ocuphire Pharma, Inc. (OCUP) Should Keep going

09:54am, Wednesday, 05'th Apr 2023

Ocuphire Pharma, Inc. (OCUP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed

What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?

01:33pm, Monday, 06'th Feb 2023

Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?

09:25am, Thursday, 26'th Jan 2023

Ocuphire Pharma (NASDAQ: OCUP ) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial. The clinical trial evaluated the use of APX3330 as a treatment for diabetic

Ocuphire to Present at Five Upcoming Investor/Industry Conferences

08:00am, Monday, 21'st Nov 2022

FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi

All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy

01:32pm, Thursday, 27'th Oct 2022

Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

07:00am, Friday, 07'th Oct 2022

Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT

Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting

08:00am, Wednesday, 08'th Jun 2022

Of 103 Diabetic Subjects Enrolled in the 24-week ZETA-1 Phase 2b Trial, 70% Have Completed 12 or More Weeks

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

08:00am, Wednesday, 11'th May 2022

FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapie

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

08:00am, Wednesday, 06'th Apr 2022

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap

Ocuphire Pharma's Shares Fall Despite Positive Data From Registrational Phase 3 Trial Of Nyxol

11:46am, Tuesday, 29'th Mar 2022

Ocuphire Pharma Inc (NASDAQ: OCUP) announced topline results from the second Phase 3 MIRA-3 trial of Nyxol to reverse pharmacologically-induced mydriasis (dilation of the pupil). The trial met it

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy

11:30am, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.

Successful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by